European reference network for rare vascular diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)?

Sophie Dupuis-Girod*, Claire L Shovlin, Anette D Kjeldsen, Hans-Jurgen Mager, Carlo Sabba, Freya Droege, Anne-Emmanuelle Fargeton, Annette D Fialla, Silvia Gandolfi, Ruben Hermann, Gennaro M Lenato, Guido Manfredi, Marco C Post, Catherine Rennie, Patrizia Suppressa, Ulrich Sure, Elisabetta Buscarini*, ePag group

*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

66 Downloads (Pure)

Fingerprint

Dive into the research topics of 'European reference network for rare vascular diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)?'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science